Targeted Oncology - Immunotherapy, Biomarkers, and Cancer …
WEBSingle CAR-T Infusion Shows Deep and Durable Responses in Relapsed Myeloma. By Caroline Seymour. October 2nd 2024. A single infusion of the autologous GPRC5D-targeted CAR T-cell therapy BMS-986393 led to high response rates in patients with relapsed/refractory multiple myeloma who received between 1 and 3 prior lines of therapy.
High-Dose Radiation Plus Long-Term ADT Improves Survival in …
WEBJan 25, 2024 · Utilizing a higher dose of radiation therapy in combination with the long-term use of androgen deprivation therapy (ADT) improved survival outcomes after 10 years of follow-up in patients with high-risk prostate cancer, according to long-term results from the GETUG-AFU 18 trial (NCT00967863) presented at the 2024 ASCO Genitourinary Cancers ...
Key Innovations and Ongoing Challenges in Multiple Myeloma …
WEBAug 16, 2024 · In an interview, Amrita Krishnan, MD, discussed several key advancements and challenges in the field of multiple myeloma. Significant advancements have transformed multiple myeloma treatment, including the development of T-cell engagers like chimeric antigen receptor (CAR) T-cell therapy and bispecific antibodies targeting multiple antigens.
Risk Stratification Tools for MDS: IPSS, IPSS-R, IPSS-M - Targeted …
WEBJan 10, 2024 · Some patients classified as low risk by IPSS-R are upstaged to higher-risk disease by IPSS-M. With 6 risk strata, IPSS-M provides more precise classification. However, clinical trials and treatment selections still rely on traditional IPSS/IPSS-R. With time, IPSS-M will be incorporated into research and practice to guide management.
Next Generation Androgen Receptor Inhibitors - Targeted Oncology
WEBNov 10, 2021 · There are currently 4 approved androgen receptor pathway inhibitors in the United States: 3 anti-androgens—apalutamide, enzalutamide, and darolutamide—and an androgen receptor pathway inhibitor, abiraterone acetate. The efficacy of these agents, while rarely studied head-to-head, appears remarkably …
Navigating Treatment Options for HER2+ BC: A Need for …
WEBAug 21, 2024 · The Playback API request failed for an unknown reason. The DAPHNe trial (NCT03716180) investigated the prevalence and dynamics of circulating tumor DNA (ctDNA) in patients with early-stage HER2-positive breast cancer undergoing neoadjuvant therapy. In the study, 92% of patients had detectable ctDNA at baseline, suggesting widespread minimal ...
Mirdametinib Scores FDA Priority Review in Neurofibromatosis …
WEBAug 28, 2024 · Mirdametinib, an investigational MEK inhibitor, has been granted priority review by the FDA for the treatment of adult and pediatric patients with NF1-PN, and a PDUFA target action date of February 28, 2025, has been set. 1. The FDA grants priority review to applications of agents that, if approved, would offer significant improvements over ...
FDA Grants T-DXd Breakthrough Therapy Designation in …
WEBAug 19, 2024 · The FDA has granted breakthrough therapy designation to fam-trastuzumab deruxtecan-nxki (T-DXd; Enhertu) in unresectable or metastatic hormone receptor-positive (HR+)/HER2-low or HER2-ultralow breast cancer. The designation is supported by data from the phase 3 DESTINY-Breast06 study (NCT04494425). T-DXd has received 8 breakthrough therapy ...
GSK5764227 Gains FDA Breakthrough Therapy Designation in ES …
WEBAug 20, 2024 · The FDA has granted breakthrough therapy designation (BTD) to GSK5764227 (GSK’227; HS-20093) in extensive-stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy. GSK’227 is an investigational B7-H3-targeted antibody-drug conjugate (ADC). The BTD is designed to accelerate the development and ...
Nivolumab Shows Improved DFS in ITT and PD-L1–High Bladder …
WEBAug 13, 2024 · Investigators demonstrated that patients with high-risk muscle-invasive bladder cancer experienced longer DFS with adjuvant nivolumab compared with placebo after radical surgery. This was seen in the intention-to-treat (ITT) population and those with positive PD-L1 expression, according to Galsky. Nivolumab continued to show benefit over ...